Navigation Links
Vantia Therapeutics' Lead Candidate VA106483 Enters Phase IIb Trial for Nocturia
Date:2/2/2010

SOUTHAMPTON, England, February 2 /PRNewswire/ -- Vantia Therapeutics, an emerging pharmaceutical company developing novel, small molecule drugs targeting large, underserved medical markets, today announces it has begun its planned Phase IIb trial of its lead development compound VA106483 for nocturia. The study is a randomised, double-blind, placebo-controlled study and is expected to recruit approximately 120 male patients at 20 centres in the US. The study will primarily assess number of nocturnal voids per night. Secondary endpoints include quality of life and sleep duration measures.

Nocturia (defined as waking to urinate at night thereby significantly disturbing sleep) is a common condition, with prevalence increasing markedly with age. It is often the presenting symptom in men with benign prostatic hypertrophy (BPH) and affects at least 70% of BPH patients. There are currently significant limitations in the treatment for nocturia and it represents a potential market estimated at more than US$1 billion.

In June last year, Vantia Therapeutics announced positive results from its Phase IIa trial of VA106483. The trial showed that oral VA106483 produced a predictable antidiuretic effect in elderly subjects, as determined by increased osmolality and decreased urine output. The study also showed that VA106483 was generally well tolerated in an elderly patient population.

VA106483 is a novel small molecule drug candidate that exerts its effect directly in the kidney by binding to vasopressin (V2) receptors, which regulate water excretion. It was discovered by scientists at Vantia Therapeutics from its extensive drug candidate library.

Dr Hilary McElwaine-Johnn, CMO of Vantia Therapeutics, said "Nocturia is a common condition, the prevalence of which increases markedly in older people. It is disruptive to sleep and can have a significant impact on the quality of life of patients. Our research suggests that only a very small percentage of patients with this symptom receive any kind of treatment. We are very pleased therefore to be starting this larger clinical study with VA106483 based on the encouraging results seen in earlier clinical studies."

Notes to Editors:

About Vantia Therapeutics

Vantia Therapeutics is an emerging pharmaceutical company developing novel, small molecule drugs targeting large, underserved medical markets. Formed in 2008 as a spin-out of Ferring Research Ltd's small molecule R&D, it has two clinical phase products, VA106483 for the treatment of nocturia and VA111913 for the treatment of dysmenorrhoea, as well as preclinical and discovery programmes based on protease inhibition with potential in the areas of oncology and inflammation. The company's investors include MVM Life Science Partners, SV Life Sciences and Novo A/S. Vantia Therapeutics Ltd is situated on Southampton Science Park, UK, where it occupies 10,000 sq ft of chemistry and biology facilities. For further information, please go to http://www.vantia.com.

About nocturia

Nocturia (defined as waking to void at night) is a common condition, with prevalence increasing markedly with age. It is often the presenting symptom of benign prostatic hypertrophy (BPH) with at least 70% of BPH patients complaining of nocturia. Whilst some symptoms of BPH are successfully addressed by the standard BPH therapies of alpha blockers and 5-alpha reductase inhibitors, nocturia remains inadequately treated. With estimates putting the number of BPH/nocturia sufferers at 55 million in the seven largest markets world wide, and only 10% of these believed to be receiving any kind of treatment, it is a clear area of unmet medical need estimated to be worth in excess of $500m. The hormone vasopressin is involved in the regulation of the body's water content and as a vasopressin agonist VA106483 has been shown to act as an anti-diuretic.


    Contact details:

    Vantia Therapeutics
    Andy Crockett, VP Business Development +44(0)238-076-3456,
    +44(0)787-255-9676 info@vantia.com

    Citigate Dewe Rogerson
    Chris Gardner, Mark Swallow, Helena Galilee +44(0)207-638-9571
    vantia@citigatedr.co.uk

SOURCE Vantia Therapeutics


'/>"/>
SOURCE Vantia Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Vantia Therapeutics Lead Candidate VA106483 Demonstrates Positive Anti-diuretic Effect in Phase IIa Trial in Nocturia
2. Vantia Therapeutics Pipeline Continues to Mature
3. Pervasis Therapeutics Receives FDA Clearance for Pivotal Phase 3 Trial of Vascugel(R)
4. Pepscan Therapeutics Strengthens Management Team
5. PTC Therapeutics Announces Additional Study of Ataluren in Patients with Advanced Nonsense Mutation Duchenne/Becker Muscular Dystrophy
6. NASDAQ Trading for Oxygen Biotherapeutics, Inc. Shares to Begin January 15, 2010
7. Echo Therapeutics Announces Major Milestone: The Completion of Product Development Work of its Revolutionary, Patented Prelude(TM) SkinPrep System
8. Advanced Cardiac Therapeutics Completes $5 Million Financing
9. Cell Therapeutics, Inc. (CTI) to Present at the 28th Annual JP Morgan Healthcare Conference
10. Oxygen Biotherapeutics, Inc. Announces Approval for NASDAQ Listing
11. Anesiva Announces Merger With Arcion Therapeutics Will Not be Completed
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)...  Robust competition in the private marketplace is resulting in ... to a new study by the Berkeley ... to examine the share of prescription medicine spending retained ... health plans and other stakeholders in the supply chain. ... show what happens when the list price of a ...
(Date:1/17/2017)... North America Insulin Delivery Market Outlook to ... Insulin Delivery Market Outlook to 2022", provides key market ... report provides value, in millions of US dollars, volume ... - Insulin Pens, Insulin Pumps, Insulin Syringes and Traditional ... shares and distribution shares data for each of these ...
(Date:1/17/2017)... , Jan 17, 2017 Research and ... Healing Materials: 2017 - 2024" report to their offering. ... This new report ... market report that was issued in May of 2015. Self-healing is ... In our previous analysis we projected a market potential of $2.7 ...
Breaking Medicine Technology:
(Date:1/18/2017)... ... January 18, 2017 , ... ... publication among specialty pharmacists and pharmacy professionals, has teamed up with Ochsner ... (SAP) program, announced Brian Haug, president of Pharmacy Healthcare Communications, LLC, publishers ...
(Date:1/18/2017)... ... January 18, 2017 , ... The Portee Insurance Agency, a family ... owners in central Maryland and the DC region, is inaugurating a charity event aimed ... nationally every year, making it the #1 killer in America. However, heart disease is ...
(Date:1/18/2017)... (PRWEB) , ... January 18, 2017 , ... ... technologies and development solutions for drugs, biologics and consumer health products, today announced ... be presenting at the upcoming WCBP Conference, to be held at the Mayflower ...
(Date:1/18/2017)... ... January 18, 2017 , ... During pregnancy, women are ... erosion, and those dental problems can increase the risk of pregnancy complications. Unfortunately, ... are failing to get the dental care they need. Agoura Hills dentist, Philip ...
(Date:1/17/2017)... York, NY (PRWEB) , ... January 17, 2017 , ... ... grand opening of a new showroom at South Dixie Hwy in Miami, FL. , ... Officer at Gym Source. “The new innovative in-store concept is designed to give clients ...
Breaking Medicine News(10 mins):